Former Pfizer Inc. CEO Jeffrey Kindler’s abrupt resignation on Dec. 5 came just in time to give the feds what they wanted: A new leadership structure at the drug giant.
While accepting Kindler’s resignation, the board of directors suddenly reversed its longstanding stance on corporate structure — announcing that Kindler’s replacement would hold the CEO job only, and that a new chairman of the board would be named later.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
